PR Newswire TechnologyCodex · 实盘不做把握 8/10
北京时间·🕒 发布 10:00:00时区推断·⟳ 抓取 10:02:31·⚡ 决策 07-11 10:03:48 +1m17s·108.4 天前
ClaimsFiler提醒GeneDx投资者证券集体诉讼首席原告申请截止日
这是一条律所/索赔服务机构发布的股东诉讼提醒，核心负面信息是2026年5月4日财报后已发生的毛利率下滑、收入指引下调和股价大跌，不是新的经营或监管催化。
📄 原文PR Newswire Technology↗ 原文
NEW ORLEANS, July 10, 2026 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that…
不做 GeneDx Holdings Corp.（WGS.US）
本条是股东诉讼首席原告截止日提醒，核心业绩下修和股价大跌发生在2026年5月4日，缺乏新的同向交易催化。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-10 · 扩散 medium · price-in 风险 high ↗
关键理由
- 这是一条律所/索赔服务机构发布的股东诉讼提醒，核心负面信息是2026年5月4日财报后已发生的毛利率下滑、收入指引下调和股价大跌，不是新的经营或监管催化。
主要风险
- 若后续出现法院实质性裁定、监管调查升级或公司再次下修指引，需要按新事件重新评估。
原文全文
展开原文 · 2,411 字
NEW ORLEANS, July 10, 2026 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until August 3, 2026 to file lead plaintiff applications in a securities class action lawsuit against GeneDx Holdings Corp. (NasdaqGS: WGS), if they purchased or otherwise acquired the Company's shares between April 16, 2025 and May 4, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the District of Connecticut.
Get Help
GeneDx investors should visit us at https://www.claimsfiler.com/cases/nasdaq-wgs/?prs=prn or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
About the Lawsuit
GeneDx and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On May 4, 2026, the Company reported its financial results for the first quarter of fiscal year 2026, disclosing a drop in adjusted gross margin from 74% to 69%, that it had missed its revenue estimates for both its exome and genome lines, and lowered its guidance for full year revenue to $475 – $490 million, down from $540 – $550 million. The Company also disclosed a $31.2 million impairment loss attributable to its prior acquisition of Fabric Genomics, an AI-driven genomic interpretation company, which the Company had touted as expected to expand its addressable market through multiple scalable revenue streams and transform static data into a recurring revenue-generating platform.
On this news, the price of GeneDx shares fell by $33.42 per share, or 49.2%.
The case is Basma v. GeneDx Holdings Corp., No. 26-cv-00880.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com.
SOURCE ClaimsFiler
Get Help
GeneDx investors should visit us at https://www.claimsfiler.com/cases/nasdaq-wgs/?prs=prn or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
About the Lawsuit
GeneDx and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On May 4, 2026, the Company reported its financial results for the first quarter of fiscal year 2026, disclosing a drop in adjusted gross margin from 74% to 69%, that it had missed its revenue estimates for both its exome and genome lines, and lowered its guidance for full year revenue to $475 – $490 million, down from $540 – $550 million. The Company also disclosed a $31.2 million impairment loss attributable to its prior acquisition of Fabric Genomics, an AI-driven genomic interpretation company, which the Company had touted as expected to expand its addressable market through multiple scalable revenue streams and transform static data into a recurring revenue-generating platform.
On this news, the price of GeneDx shares fell by $33.42 per share, or 49.2%.
The case is Basma v. GeneDx Holdings Corp., No. 26-cv-00880.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com.
SOURCE ClaimsFiler
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。